Mangalam Drugs & Organics Ltd. · NSE:MANGALAM
Mangalam Drugs & Organics — Investor Presentation (January 2016)
27 slides from Mangalam Drugs & Organics's investor presentation, January 2016
Slide 1: Investor Presentation January 2016
Investor Presentation January 2016
Slide 2: Table of Contents
Table of Contents Executive Summary Company Overview Business Overview Industry Overview Financial Overview
Slide 3: Executive Summary
E/ Executive Summary ge -P\sBe9 & Mangalam Drugs & Organics Ltd.
Slide 4: Executive Summary
Executive Summary Overview • Mangalam Drugs & Organics Ltd. (Mangalam) was incorporated in 1972 and is one of the largest suppliers and manufacturers of Anti-Malarial Active Pharmaceuticals Ingredients (API) in the world. • The company’s headquarter is in Mumbai, with two manufacturing facilites at
Slide 5: Company Overview
Company Overview Compan ro. oe -¥\38ee 5 & Mangalam Drugs & Organics Ltd.
Slide 6: Company Overview
Company Overview Mangalam Drugs & Organics LTD. was incorporated in 1972, commenced operations in 1977, and was listed on BSE and Revenue Growth (INR Mn) NSE in 2005-06. The Company has a market capitalization of around Rs. 2,570 Mn (as of 31st December 2015) Well established player in an Indust
Slide 7: Key Milestones
Started Anti-Retroviral API Production Key Milestones First approval from EDQM for Nimesulide Upgraded Facility 1 Approval from Bill Mangalam Drugs & Organics Ltd was formed Clinton Foundation 2014 2015 2011 2010 Full fledged public limited 2008 2006 2004 Further API Commenced Operations 2002 produc
Slide 8: Key Strengths
Key Strengths Competitive Presence in Focus on R&D & Premier Entry Barrier Position Regulatory Market Diversification Certifications India’s major Anti- 2-3 years on an Largest malarial API 10% of the total WHO approvals for average for a new manufacturer of manufacturer to work force are 7 Anti-mal
Slide 9: Executive Director
Executive Director Mr. Govardhan M. Dhoot (Chairman & Whole Time Director) Mr. Govardhan Murlidhar Dhoot has been with the company since inception. He has been an instrumental in increasing the exports of the Company and expanding and diversifying the company from chemical manufacturer to a larg
Slide 10: Manufacturing Facilities at Vapi, Gujarat
Manufacturing Facilities at Vapi, Gujarat Facility 1 (WHO approved) Facility 2 Total Production area: 3059 Sq. m Total Production area: 3272 Sq. m Total 1 API manufacturing, 1 2 API manufacturing and 1 solvent intermediate manufacturing, 1 pilot recovery block plant & 1 recovery blocks API
Slide 11: Research & Development
Research & Development The company has a strong focus on R&D on new products and therapeutic segments. There is a highly qualified team of 20+ research scientists World class laboratory with state of the art technology. Non-infringing process > Patentable process The laboratory has been ap
Slide 12: Business Overview
Business Overview io. oe -¥\38ee & Mangalam Drugs & Organics Ltd.
Slide 13: Malaria: Global Phenomenon
Malaria: Global Phenomenon In 2014, 97 countries and territories had on-going malaria transmission − Malaria is presently endemic in a broad band around the Malaria Prevalence equator, in areas of the Americas, many parts of Asia, and much of Africa An estimated 3.3 billion people are at risk of
Slide 14: Addressing Malaria With Multiple Products
Addressing Malaria With Multiple Products There are no permanent preventions or vaccines against malaria Revenue Split (%) of Mangalam as of today. for FY14-15 Following Anti-Malarial APIs are produced by the company: − Arthemether 24% − Lumefantine 33% − Artesunate − Amodiaquine Hydrochloride −
Slide 15: Going beyond Malaria: Anti-Retroviral
Going beyond Malaria: Anti-Retroviral Strong Market Requirement ARV APIs Current production of ARV drugs meets only 50% of API Name Status total demand Tenofovir Disoproxyl Commercialized Strong focus on increasing available of medication to Emtricitabine Under process validation on pilot infect
Slide 16: Other Products
Other Products Uricosuric Agent :Allopurinol Used in treatment of gout or kidney stone Reduces the production of uric acid in the body, primary cause for gout or kidney stones WHO essential medicines for basic health system Used in medication for ischemic reperfusion injury, poor kidney func
Slide 17: Global Customer Base
Global Customer Base DOMESTIC: INTERNATIONAL: 17
Slide 18: Industry Overview
Industry Overview OR! -P\sBe8 & Mangalam Drugs & Organics Ltd. "owl
Slide 19: Overview: Indian Pharma Market
Overview: Indian Pharma Market Indian Pharmaceutical Sector Revenue 3rd largest in the world in terms of volume in the (USD Mn) Global API Market. 55 Fastest growing pharma market in the world Generics drugs is the largest segment of the Indian 12 Pharma market with72% market share in terms of
Slide 20: Key Growth Drivers: Indian Pharma Market
Key Growth Drivers: Indian Pharma Market Cost efficiency: Relative Cost of Production with USA The Indian Pharma cost is almost 60% less compared to USA cost as base as on March 2014 and half of the cost in Europe Economic Growth: 100 Drug affordability, penetration in healthcare sector and 85 C
Slide 21: Overview: Indian API Market
Overview: Indian API Market Expected to be the 3rd largest API merchant market by the end of 2016 with a market share of 7.2% in the world. The Indian API industry has the second most largest number of Abbreviated New Drug Applications (ANDAs) Market Share of API: 2016 (E) API Industry of Indi
Slide 22: Financial Overview
Ea Financial Overview i te “S\38ae & Mangalam Drugs & Organics Ltd.
Slide 23: Profit and Loss Statement
Profit and Loss Statement Income Statement (INR Mn) FY12 FY13 FY14 FY15 9M-FY16 Total Income 1,538 1,253 1,227 2,207 2,245 Expenses 1,391 1,297 1,129 2,003 2,012 EBITDA 147 (44) 98 204 233 EBITDA Margin 9.6% (3.5%) 8.0% 9.2% 10.4% Depreciation 37 39 40 42 33 Finance Cost 102 100 97 103 65 Other Inco
Slide 24: Balance Sheet
Balance Sheet Equity and Liabilities (INR Mn.) FY13 FY14 FY15 H1-FY16 Assets (INR Mn.) FY13 FY14 FY15 H1-FY16 Shareholders Fund Fixed assets Share Capital 132 132 132 132 Total Fixed Assets 551 534 530 525 Reserves and Surplus 131 100 162 227 Money Received - - - 155 Net worth 263 232 294 514 Non Cu
Slide 25: Financial Charts: A Turnaround Story
Financial Charts: A Turnaround Story Total Revenue Net D/E (x) PAT & PAT Margins % 2,207 3.1 80 2.78% 61 4.00% 2.8 60 0.41% 2.00% 2.4 40 1,541 20 6 0.00% 1,268 1,228 0 -2.00% 1.4 -20 FY12 FY13 FY14 FY15 -4.00% -40 -30 -2.48% -6.00% -60 -80 -8.00% -100 -10.00% -120 -9.42% FY12 FY13 FY14 FY15 FY12 FY1
Slide 26: Capital Market
Capital Market 2500% 2000% 1500% 1000% Manglam Sensex 500% 0% -500% Shareholding Structure (as on 31st Jan 2015) Price Data (As of 31st December 2015) INR Face Value 10 Market Price 195 Public, 52 Week H/L 441.5/17.4 54.20% Promoters Market Cap (INR Mn) 2,570 , 45.80% Equity Shares Outstanding (Mn)
Slide 27: Disclaimer
Disclaimer Mangalam Drugs and Organics Ltd No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in al
Mangalam Drugs & Organics — Investor Presentation (January 2016) on 6ix